ArticleJournal of pharmaceutical policy and practice2026
Development and validation of deprescribing algorithms for kidney failure using consensus development methodology.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with kidney failure (KF) are at high risk of inappropriate polypharmacy; however, this can be mitigated through deprescribing. While several evidence-based deprescribing guidelines exist for various patient populations, their applicability and utility in KF settings remain limited. Aim: This study aimed to adapt existing evidence on deprescribing in KF to develop practical deprescribing algorithms that support clinicians in implementing deprescribing interventions in KF care. Methods: Available evidence about deprescribing in KF was reviewed, and local prescribing trends among KF patients were explored. Second, a panel of five experts in pharmacotherapy, medication safety, and clinical research was convened and conducted consensus development workshops to appraise the evidence and develop comprehensive deprescribing algorithms for patients with KF. The adapted algorithms were reviewed by nephrology consultants ( Results: One general and 18 drug class-specific evidence-based deprescribing algorithms in KF care were developed. These provide a structured, stepwise approach to assessing medication appropriateness and guiding deprescribing decisions. Expert validation resulted in refinements of the algorithms. In the pilot testing among hemodialysis (HD) and low clearance clinics, the generic deprescribing algorithm was applied in all cases. The drug-class-specific algorithms were used in 41 deprescribing plans (55.4%) in the HD and in 5 (45.5%) in the low-clearance clinic settings. Conclusion: We developed and validated a set of evidence-based deprescribing algorithms tailored to patients with KF, offering a practical and structured approach to support clinicians in deprescribing potentially inappropriate medications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.